Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Clinical trial NCT04191096 · COMPLETED
Trial details
- NCT number
- NCT04191096
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-12
- Primary completion
- 2022-10-31
- Enrollment
- 1251
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.